Company / Free Cash Flow per Share
CRISPR Therapeutics AG Free Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow per Share
-$4.03
FY2025
5-year range
-$6.92 / $6.19
FY2021-FY2025
Trend
-123.2%
vs FY2024
Sector context
#167 of 190
Health Care
What the data says
CRISPR Therapeutics AG's free cash flow per share of $-4.03 is lower than 88% of companies in the Health Care sector (FY2025). Free Cash Flow per Share has fluctuated over the past 10 years, ranging from $-10.11 in FY2016 to $6.19 in FY2021.
Based on SEC 10-K filings.
-4.03 in FY2025.
Declined from $-3.44 to $-4.03 over the past 2 years.
Health Care sector context is included.
Free Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 12% in Health CareTop 88% of 190This company -$4.03 Sector average $3.32
▼
-221.3% below sector average
Key checks
Key Insights
- In FY2025, free cash flow per share decreased 123.2% year-over-year.
- Ranks #167 out of 190 companies in the Health Care sector.
- Peak free cash flow per share was recorded in FY2021.
- Lowest free cash flow per share in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$4.03 | -123.2% |
| FY2024 | -$1.81 | +47.4% |
| FY2023 | -$3.44 | +50.3% |
| FY2022 | -$6.92 | -211.9% |
| FY2021 | $6.19 | +246.5% |
| FY2020 | -$4.22 | -538.1% |
| FY2019 | $0.96 | +139.5% |
| FY2018 | -$2.44 | -24.4% |
| FY2017 | -$1.96 | +80.6% |
| FY2016 | -$10.11 | -187.4% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026